PCR联合HPV检测在宫颈癌筛查中的应用
|
摘要
目的探讨荧光PCR法联合高危型人乳头瘤病毒(HPV)分型核酸测定在宫颈癌癌前病变筛查中的应用及其临床效果。方法选取2016年4月～2018年4月我院收治的宫颈癌患者86例,分为对照组和研究组,对照组患者接受荧光PCR法进行检测筛查,研究组患者在应用荧光PCR法的基础上联合高危型人乳头瘤病毒分型核酸测定进行筛查,同病理诊断结果进行对比。结果研究组检测出的高危型人乳头瘤病毒感染率高达75.6%,研究组检测出的高危型人乳头瘤病毒感染率高于对照组(P<0.05),40～49岁年龄段的人群感染率最高为82.1%,不同年龄阶段高危型人乳头瘤病毒感染的情况不同(P<0.05)。结论荧光PCR法联合高危型人乳头瘤病毒分型核酸测定在宫颈癌癌前病变筛查当中有着非常重要的作用以及对于医学检测具有指导意义,检出率更高,效果理想,临床上应当进一步推广应用。
Objective To explore the application of fluorescent PCR combined with high-risk human papillomavirus typing nucleic acid in the screening of cervical cancer precancerous lesions and its clinical effect. Methods 86 patients with cervical cancer admitted in our hospital from April 2016 to April 2018 were divided into the control group and the study group. The control group was screened by fluorescent PCR. The patients in the study group were treated with the screening of high-risk human papillomavirus typing nucleic acid based on fluorescent PCR. The pathological diagnosis results were compared. Results The high-risk human papillomavirus infection rate detected by the study group was as high as 75.6%. The high-risk human papillomavirus infection rate detected by the study group was higher than that of the control group(P<0.05). The population infection rate of people aged 40-49 years old was as high as 82.1%. And the high-risk human papillomavirus infection was different at different ages(P<0.05). Conclusion Fluorescence PCR combined with high-risk human papillomavirus typing nucleic acid has a very important role in the screening of cervical cancer precancerous lesions and has a guiding role in medical testing. The detection rate is higher and the effect is ideal. It should be further promoted the applied clinically.
Objective To explore the application of fluorescent PCR combined with high-risk human papillomavirus typing nucleic acid in the screening of cervical cancer precancerous lesions and its clinical effect. Methods 86 patients with cervical cancer admitted in our hospital from April 2016 to April 2018 were divided into the control group and the study group. The control group was screened by fluorescent PCR. The patients in the study group were treated with the screening of high-risk human papillomavirus typing nucleic acid based on fluorescent PCR. The pathological diagnosis results were compared. Results The high-risk human papillomavirus infection rate detected by the study group was as high as 75.6%. The high-risk human papillomavirus infection rate detected by the study group was higher than that of the control group(P<0.05). The population infection rate of people aged 40-49 years old was as high as 82.1%. And the high-risk human papillomavirus infection was different at different ages(P<0.05). Conclusion Fluorescence PCR combined with high-risk human papillomavirus typing nucleic acid has a very important role in the screening of cervical cancer precancerous lesions and has a guiding role in medical testing. The detection rate is higher and the effect is ideal. It should be further promoted the applied clinically.
引文
[1]贺国丽,吴秀荣,郑碧娟.宫颈癌与癌前病变中高危人乳头瘤病毒型别特征及差异分析[J].实用妇产科杂志,2016,32(6):459-461.
[2]Tsakogiannis D,Moschonas GD,Bella E,et al.Association of p16(CDKN2A)polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population[J].Journal of Medical Virology,2018,90(5):965-971.
[3]齐艳红.宫颈病变筛查中宫颈液基薄层细胞学检查与HPVDNA检测的联合应用观察[J].山东医药,2016,56(19):58-59.
[4]赵超,赵昀,崔淑慧,等.子宫颈液基细胞学、高危型HPV及联合检测在子宫颈癌机会性筛查中的价值[J].中国妇产科临床杂志,2016,28(2):119-121.
[5]徐舜,陈洁瑛,江海燕,等.宫颈癌前病变HPV感染与宫颈液基细胞早期筛查的临床分析[J].中华医院感染学杂志,2017,27(20):4739-4742.
[6]宋艳波,王少明,董丹,等.内蒙古地区液基细胞学与人乳头瘤病毒分型检测筛查宫颈癌的对比研究[J].中国妇产科临床杂志,2016,17(1):10-11.
[7]Mittal S,Basu P,Muwonge R,et al.Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study[J].International Journal of Cancer,2017,140(8):1850-1859.
[8]陶志梅,潘敏,俞美娟,等.高危型人乳头瘤病毒感染联合液基薄层细胞检测对宫颈癌及宫颈癌前病变筛查与随访的临床意义[J].中华医院感染学杂志,2017,27(10):2340-2343.
[9]吴翠霞,张艳红,葛小花,等.高危型HPV感染与宫颈癌前病变与宫颈癌的相关性研究[J].中华医院感染学杂志,2016,26(11):2568-2570.
[10]Torii Y,Fujii T,Kukimoto I,et al.Comparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution[J].Cancer Science,2016,107(10):1520-1526.
[11]万晓春,周晓燕,平波,等.九价HPV疫苗所针对的高危型HPV亚型在宫颈癌及其癌前病变中应用有效性的初步预测[J].中国癌症杂志,2017,27(7):552-558.
[12]张倩,胡尚英,冯瑞梅,等.高危型人乳头瘤病毒感染变化与宫颈癌及癌前病变发病风险的15年前瞻队列随访研究[J].中华肿瘤杂志,2016,38(10):792-797.
[13]Badiga S,Chambers MM,Huh W,et al.Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines[J].Cancer,2016,122(23):3615-3623.
[14]李凌,李隆玉,杨起楠,等.高危型HPV载量与分型检测对宫颈高级别病变预测价值的前瞻性队列研究[J].中国肿瘤临床,2016,43(9):376-380.
[15]Liu G,Sharma M,Tan N,et al.HIV-positive women have higher risk of HPV infection,precancerouslesions,and cervical cancer:A systematic review and meta-analysis[J].Aids,2018,32(6):1245-1378.
[16]Mejía L,Mu觡oz D,Trueba G,et al.Prevalence of human papillomavirus types in cervical cancerous and precancerous lesions of Ecuadorian women[J].Journal of Medical Virology,2016,88(12):2021-2278.
[17]王晓光,辛志峰,李娜,等.人乳头瘤病毒检测与薄层液基细胞学技术在宫颈癌筛查中的应用[J].现代妇产科进展,2016,25(2):140-142.
[18]Jiménez-Wences H,Martínez-Carrillo DN,Peralta-Zaragoza O,etal.Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection[J].Oncology Reports,2016,35(4):2297-2389.
[19]张淼,周秀春,张冠群.人乳头瘤病毒检测及TCT检查在宫颈癌筛查中的临床价值研究[J].现代预防医学,2016,43(5):836-838.
[20]Wang X,Cheng K,Han Y,et al.Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADRCells[J].Biological&Pharmaceutical Bulletin,2016,39(5):815-822.
[2]Tsakogiannis D,Moschonas GD,Bella E,et al.Association of p16(CDKN2A)polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population[J].Journal of Medical Virology,2018,90(5):965-971.
[3]齐艳红.宫颈病变筛查中宫颈液基薄层细胞学检查与HPVDNA检测的联合应用观察[J].山东医药,2016,56(19):58-59.
[4]赵超,赵昀,崔淑慧,等.子宫颈液基细胞学、高危型HPV及联合检测在子宫颈癌机会性筛查中的价值[J].中国妇产科临床杂志,2016,28(2):119-121.
[5]徐舜,陈洁瑛,江海燕,等.宫颈癌前病变HPV感染与宫颈液基细胞早期筛查的临床分析[J].中华医院感染学杂志,2017,27(20):4739-4742.
[6]宋艳波,王少明,董丹,等.内蒙古地区液基细胞学与人乳头瘤病毒分型检测筛查宫颈癌的对比研究[J].中国妇产科临床杂志,2016,17(1):10-11.
[7]Mittal S,Basu P,Muwonge R,et al.Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study[J].International Journal of Cancer,2017,140(8):1850-1859.
[8]陶志梅,潘敏,俞美娟,等.高危型人乳头瘤病毒感染联合液基薄层细胞检测对宫颈癌及宫颈癌前病变筛查与随访的临床意义[J].中华医院感染学杂志,2017,27(10):2340-2343.
[9]吴翠霞,张艳红,葛小花,等.高危型HPV感染与宫颈癌前病变与宫颈癌的相关性研究[J].中华医院感染学杂志,2016,26(11):2568-2570.
[10]Torii Y,Fujii T,Kukimoto I,et al.Comparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution[J].Cancer Science,2016,107(10):1520-1526.
[11]万晓春,周晓燕,平波,等.九价HPV疫苗所针对的高危型HPV亚型在宫颈癌及其癌前病变中应用有效性的初步预测[J].中国癌症杂志,2017,27(7):552-558.
[12]张倩,胡尚英,冯瑞梅,等.高危型人乳头瘤病毒感染变化与宫颈癌及癌前病变发病风险的15年前瞻队列随访研究[J].中华肿瘤杂志,2016,38(10):792-797.
[13]Badiga S,Chambers MM,Huh W,et al.Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines[J].Cancer,2016,122(23):3615-3623.
[14]李凌,李隆玉,杨起楠,等.高危型HPV载量与分型检测对宫颈高级别病变预测价值的前瞻性队列研究[J].中国肿瘤临床,2016,43(9):376-380.
[15]Liu G,Sharma M,Tan N,et al.HIV-positive women have higher risk of HPV infection,precancerouslesions,and cervical cancer:A systematic review and meta-analysis[J].Aids,2018,32(6):1245-1378.
[16]Mejía L,Mu觡oz D,Trueba G,et al.Prevalence of human papillomavirus types in cervical cancerous and precancerous lesions of Ecuadorian women[J].Journal of Medical Virology,2016,88(12):2021-2278.
[17]王晓光,辛志峰,李娜,等.人乳头瘤病毒检测与薄层液基细胞学技术在宫颈癌筛查中的应用[J].现代妇产科进展,2016,25(2):140-142.
[18]Jiménez-Wences H,Martínez-Carrillo DN,Peralta-Zaragoza O,etal.Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection[J].Oncology Reports,2016,35(4):2297-2389.
[19]张淼,周秀春,张冠群.人乳头瘤病毒检测及TCT检查在宫颈癌筛查中的临床价值研究[J].现代预防医学,2016,43(5):836-838.
[20]Wang X,Cheng K,Han Y,et al.Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADRCells[J].Biological&Pharmaceutical Bulletin,2016,39(5):815-822.